18x106 UI polvo para solución inyectable o para perfusión

DRUG3 trials

Sponsors

Cellectis, Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBELL, Vall D Hebron Institute Of Oncology

Conditions

Advanced selected solid tumors: melanomaAdvanced solid tumorsRelapsed or refractory B-cell Non-Hodgkin lymphomanon-small cell lung cancer (NSCLC) and cervical cancer.

Phase 1

Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

RecruitingCTIS2022-501607-27-00

CellectisRelapsed or refractory B-cell Non-Hodgkin lymphoma

Start: 2026-01-06Target: 48Updated: 2026-01-08

Phase 2

A phase 2, Multicenter Study of TILs Treatment in Advanced Tumors with Alterations in the SWI/SNF Complex: the TILTS Study

RecruitingCTIS2023-504632-17-00

Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBELLAdvanced solid tumors

Start: 2024-08-14Target: 11Updated: 2025-08-19

Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL

RecruitingCTIS2023-506400-99-00

Vall D Hebron Institute Of OncologyAdvanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

Start: 2025-01-15Target: 24Updated: 2025-12-02

Related Papers

Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study

Future Oncology2024-08-12

A phase 2, multicenter study of TILs treatment in advanced tumors with alterations in the SWI/SNF complex: The TILTS study.

Journal of Clinical Oncology2024-06-01